Francisca Ferrer‐Marín

2.5k total citations
66 papers, 1.2k citations indexed

About

Francisca Ferrer‐Marín is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Francisca Ferrer‐Marín has authored 66 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Hematology, 37 papers in Genetics and 19 papers in Molecular Biology. Recurrent topics in Francisca Ferrer‐Marín's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (29 papers), Platelet Disorders and Treatments (18 papers) and Eosinophilic Disorders and Syndromes (15 papers). Francisca Ferrer‐Marín is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (29 papers), Platelet Disorders and Treatments (18 papers) and Eosinophilic Disorders and Syndromes (15 papers). Francisca Ferrer‐Marín collaborates with scholars based in Spain, United States and United Kingdom. Francisca Ferrer‐Marín's co-authors include Martha Sola‐Visner, Vicente Vicente, José Rivera, Raúl Teruel‐Montoya, Juan Carlos Hernández‐Boluda, Alberto Álvarez‐Larrán, Francisco Cervantes, Ravi Kumar Gutti, Carles Besses and Montse Gómez and has published in prestigious journals such as Blood, PLoS ONE and International Journal of Molecular Sciences.

In The Last Decade

Francisca Ferrer‐Marín

61 papers receiving 1.2k citations

Peers

Countries citing papers authored by Francisca Ferrer‐Marín

Since Specialization

Citations

This map shows the geographic impact of Francisca Ferrer‐Marín's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francisca Ferrer‐Marín with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francisca Ferrer‐Marín more than expected).

Fields of papers citing papers by Francisca Ferrer‐Marín

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francisca Ferrer‐Marín. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francisca Ferrer‐Marín. The network helps show where Francisca Ferrer‐Marín may publish in the future.

Co-authorship network of co-authors of Francisca Ferrer‐Marín

This figure shows the co-authorship network connecting the top 25 collaborators of Francisca Ferrer‐Marín. A scholar is included among the top collaborators of Francisca Ferrer‐Marín based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francisca Ferrer‐Marín. Francisca Ferrer‐Marín is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Genomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology 2024 ·Annals of Hematology ·(unknown), Mònica López‐Guerra, Juan Carlos García‐Pagán, Eduardo Arellano‐Rodrigo, Francisca Ferrer‐Marín, Juan Carlos Hernández‐Boluda, Beatríz Bellosillo, Meritxell Nomdedéu, Virginia Hernández–Gea, (unknown), Francesca Guijarro, (unknown), Anna Baiges, Fanny Turón, Dolors Colomer, Francisco Cervantes, Alberto Álvarez‐Larrán	1
2	Essential thrombocythaemia: A contemporary approach with new drugs on the horizon 2024 ·British Journal of Haematology ·Francisca Ferrer‐Marín, Juan Carlos Hernández‐Boluda, Alberto Álvarez‐Larrán	1
3	miR‐146a^−/− mice model reveals that NF‐κB inhibition reverts inflammation‐driven myelofibrosis‐like phenotype 2024 ·American Journal of Hematology ·(unknown), (unknown), (unknown), María Luz Morales, Marı́a Luisa Lozano, Rocío Gónzález‐Conejero, Constantino Martı́nez, Raúl Teruel‐Montoya, Francisca Ferrer‐Marín	2
4	Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study 2024 ·Annals of Hematology ·(unknown), Raquel De Paz Arias, (unknown), (unknown), Ángel Ramírez Páyer, Magdalena Sierra, Francisca Ferrer‐Marín, (unknown), (unknown), Juan Luis Steegmann, María Teresa Gómez‐Casares, Joaquín Martínez‐López, Valentín García‐Gutiérrez	1
5	Pacritinib prevents inflammation-driven myelofibrosis-like phenotype in a miR-146a murine model 2024 ·Biomedicine & Pharmacotherapy ·(unknown), Constantino Martı́nez, María Luz Morales, (unknown), (unknown), (unknown), (unknown), Marı́a Luisa Lozano, Rocío Gónzález‐Conejero, Raúl Teruel‐Montoya, Francisca Ferrer‐Marín	0
6	Efficacy of Consolidation Therapy with Ponatinib 15mg on Treatment-Free Remission Rate in Patients with Chronic Myeloid Leukemia. Results of the Ponazero Trial 2023 ·Blood ·(unknown), Juan Carlos Hernández‐Boluda, (unknown), María Teresa Gómez‐Casares, Rosa Ayala, Blanca Xicoy, Francisca Ferrer‐Marín, Guillermo Ortí, Raquel De Paz Arias, (unknown), (unknown), Elvira Mora, (unknown), (unknown), Concepción Boqué, (unknown), Joaquín Martínez‐López, Valentín García‐Gutiérrez	1
7	SARAF overexpression impairs thrombin‐induced Ca ²⁺ homeostasis in neonatal platelets 2023 ·British Journal of Haematology ·Alejandro Berna‐Erro, (unknown), Raúl Teruel‐Montoya, Francisca Ferrer‐Marín, (unknown), (unknown), (unknown), (unknown), José A. Tapia, Pedro C. Redondo	0
8	Deepening Our Understanding of the Factors Affecting Landscape of Myeloproliferative Neoplasms: What Do We Know about Them? 2023 ·Cancers ·María Luz Morales, Francisca Ferrer‐Marín	1
9	Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis 2022 ·Cancers ·(unknown), Juan Carlos Hernández‐Boluda, Alberto Álvarez‐Larrán, José María Raya, Anna Angona, Natàlia Estrada, María Laura Fox, Beatriz Cuevas, (unknown), María Teresa Gómez‐Casares, Francisca Ferrer‐Marín, Silvana Saavedra, Francisco Cervantes, (unknown), (unknown)	3
10	Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib 2021 ·Journal of Clinical Medicine ·Sílvia Marcé, Blanca Xicoy, Olga García, (unknown), Natàlia Estrada, (unknown), Concepción Boqué, (unknown), Anna Angona, Raúl Teruel‐Montoya, Francisca Ferrer‐Marín, Paula Amat, Juan Carlos Hernández‐Boluda, (unknown), Eduardo Anguita, Montserrat Cortés, (unknown), (unknown), Lurdes Zamora, (unknown)	11
11	Hydroxyurea Reduces Neutrophil Extracellular Trap Formation in Myeloproliferative Neoplasms 2020 ·Blood ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Sonia Águila, (unknown), (unknown), Rocío Gónzález‐Conejero, Constantino Martı́nez, Vicente Vicente, Alberto Álvarez‐Larrán, Beatríz Bellosillo, Raúl Teruel‐Montoya, Francisca Ferrer‐Marín	2
12	Developmental Stage–Specific Manifestations of Absent TPO/c-MPL Signalling in Newborn Mice 2017 ·Thrombosis and Haemostasis ·Viola Lorenz, Haley E. Ramsey, (unknown), Joseph E. Italiano, Karin M. Hoffmeister, (unknown), Donald E. Mager, Zhongbo Hu, William B. Slayton, Benjamin T. Kile, Martha Sola‐Visner, Francisca Ferrer‐Marín	12
13	Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response 2016 ·Annals of Hematology ·(unknown), Francisco Cervantes, Juan Gonzalo Correa, (unknown), Valentín García‐Gutiérrez, (unknown), Dolors Colomer, Antonio Jiménez‐Velasco, J. L. Steegmann, Fermín Sánchez‐Guijo, Francisca Ferrer‐Marín, Arturo Pereira, Santiago Osorio	28
14	Long-term results of prednisone treatment for the anemia of myelofibrosis 2015 ·Leukemia & lymphoma ·Juan Carlos Hernández‐Boluda, Alejandra Martínez‐Trillos, Valentín García‐Gutiérrez, Francisca Ferrer‐Marín, Blanca Xicoy, Alberto Álvarez‐Larrán, Ana Kerguelen, Pere Barba, Montse Gómez, (unknown), Juan Gonzalo Correa, Francisco Cervantes	15
15	An atypical IgM class platelet cold agglutinin induces GPVI-dependent aggregation of human platelets 2015 ·Thrombosis and Haemostasis ·(unknown), Irene Martínez‐Martínez, Constantino Martı́nez, José Navarro‐Fernández, (unknown), Francisca Ferrer‐Marín, Vicente Vicente, Steve P. Watson, Robert K. Andrews, Elizabeth E. Gardiner, José Rivera, Marı́a Luisa Lozano	6
16	Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide 2013 ·Annals of Hematology ·(unknown), Juan Carlos Hernández‐Boluda, Arturo Pereira, Francisco Cervantes, Montse Gómez, Eduardo Arellano‐Rodrigo, Alberto Álvarez‐Larrán, Francisca Ferrer‐Marín, Ana Kerguelen, José Antonio Márquez, María Luisa Antelo, Carles Besses	25
17	Leukaemic Transformation in Patients with Haematological Disease Receiving Tumour Necrosis Factor Inhibitors 2012 ·Clinical Drug Investigation ·Francisca Ferrer‐Marín, María Luz Amigo, Vicente Vicente	3
18	Effects of in vitro adult platelet transfusions on neonatal hemostasis 2011 ·Journal of Thrombosis and Haemostasis ·Francisca Ferrer‐Marín, (unknown), Michael Lampa, Alan D. Michelson, Andrew L. Frelinger, Martha Sola‐Visner	54
19	Neonatal Thrombocytopenia and Megakaryocytopoiesis 2010 ·Seminars in Hematology ·Francisca Ferrer‐Marín, Zhijian Liu, Ravi Kumar Gutti, Martha Sola‐Visner	34
20	Actitudes y conocimientos de la enfermería frente al sida. Análisis de su evolución entre 1991 y 2001 2002 ·Francisca Ferrer‐Marín	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact